TN2009000147A1 - Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione - Google Patents

Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione

Info

Publication number
TN2009000147A1
TN2009000147A1 TNP2009000147A TN2009000147A TN2009000147A1 TN 2009000147 A1 TN2009000147 A1 TN 2009000147A1 TN P2009000147 A TNP2009000147 A TN P2009000147A TN 2009000147 A TN2009000147 A TN 2009000147A TN 2009000147 A1 TN2009000147 A1 TN 2009000147A1
Authority
TN
Tunisia
Prior art keywords
quinazolin
piperazin
indol
pyrrole
methyl
Prior art date
Application number
TNP2009000147A
Other languages
English (en)
Inventor
Piotr Karpinski
Stephanie Monnier
Elias Ndzie
Dimitris Papoutsakis
Paul Allen Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000147A1 publication Critical patent/TN2009000147A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000147A 2006-10-20 2009-04-17 Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione TN2009000147A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338406P 2006-10-20 2006-10-20
PCT/US2007/022241 WO2008051440A1 (fr) 2006-10-20 2007-10-18 Modifications cristallines

Publications (1)

Publication Number Publication Date
TN2009000147A1 true TN2009000147A1 (en) 2010-10-18

Family

ID=38921707

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000147A TN2009000147A1 (en) 2006-10-20 2009-04-17 Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione

Country Status (23)

Country Link
US (1) US8865897B2 (fr)
EP (1) EP2102195A1 (fr)
JP (1) JP5302199B2 (fr)
KR (1) KR20090073231A (fr)
CN (2) CN101522664B (fr)
AR (1) AR063491A1 (fr)
AU (1) AU2007309558B2 (fr)
BR (1) BRPI0717461A2 (fr)
CA (1) CA2666965A1 (fr)
CL (1) CL2007003006A1 (fr)
EC (1) ECSP099344A (fr)
IL (1) IL197962A (fr)
MA (1) MA30886B1 (fr)
MX (1) MX2009004048A (fr)
MY (1) MY158026A (fr)
NO (1) NO20091970L (fr)
NZ (1) NZ576241A (fr)
PE (1) PE20081133A1 (fr)
RU (1) RU2481341C2 (fr)
TN (1) TN2009000147A1 (fr)
TW (1) TWI399374B (fr)
WO (1) WO2008051440A1 (fr)
ZA (1) ZA200902048B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112479A1 (fr) * 2007-03-09 2008-09-18 Novartis Ag Composés
US9017528B2 (en) 2011-04-14 2015-04-28 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9005409B2 (en) 2011-04-14 2015-04-14 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9303329B2 (en) 2013-11-11 2016-04-05 Tel Nexx, Inc. Electrochemical deposition apparatus with remote catholyte fluid management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159378A1 (en) * 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
CA2690243A1 (fr) 2007-06-18 2008-12-24 Sanofi-Aventis Derives du pyrrole en tant qu'antagonistes de p2y12

Also Published As

Publication number Publication date
IL197962A (en) 2013-08-29
ZA200902048B (en) 2010-01-27
CN101522664B (zh) 2013-06-12
KR20090073231A (ko) 2009-07-02
WO2008051440A1 (fr) 2008-05-02
MX2009004048A (es) 2009-04-27
TW200829572A (en) 2008-07-16
JP5302199B2 (ja) 2013-10-02
PE20081133A1 (es) 2008-09-16
ECSP099344A (es) 2009-06-30
EP2102195A1 (fr) 2009-09-23
AU2007309558B2 (en) 2012-05-24
CN103265533A (zh) 2013-08-28
IL197962A0 (en) 2009-12-24
AU2007309558A1 (en) 2008-05-02
TWI399374B (zh) 2013-06-21
AR063491A1 (es) 2009-01-28
CL2007003006A1 (es) 2008-05-23
RU2481341C2 (ru) 2013-05-10
NO20091970L (no) 2009-05-20
MY158026A (en) 2016-08-30
US8865897B2 (en) 2014-10-21
RU2009118816A (ru) 2010-11-27
CA2666965A1 (fr) 2008-05-02
CN101522664A (zh) 2009-09-02
NZ576241A (en) 2012-05-25
BRPI0717461A2 (pt) 2013-10-08
US20100041884A1 (en) 2010-02-18
MA30886B1 (fr) 2009-11-02
JP2010506927A (ja) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2010002655A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
TW200626068A (en) Active compounds for seed treatment
UA101346C2 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды
MY146989A (en) Kinase inhibitors
MX2009010595A (es) Derivados de pirrolopirimidina.
UA101057C2 (en) Pyrimidine derivatives as kinase inhibitors
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
TW200618800A (en) Heterocyclic compounds
SG170772A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
UA104731C2 (ru) Ингибиторы р38 мар-киназ
TW200621721A (en) Methods of preparing indazole compounds
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2008061108A3 (fr) Dérivés de phtalazine
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2009004947A (es) Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2009007336A (es) Indazoles substituidos con 5-furopiridinona.
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.